ライフサイエンスコーパス: photodynamic therapy

1 stasis at various time points post-PDT (post photodynamic therapy).

2 sensitizers for photocontrolled-delivery and photodynamic therapy.

3 erved between added reovirus before or after photodynamic therapy.

4 a history of choroidal neovascularization or photodynamic therapy.

5 orescence probes, as well as sensitizers for photodynamic therapy.

6 al wastewater treatment, photochemistry, and photodynamic therapy.

7 oninvasive optical imaging, optogenetics and photodynamic therapy.

8 ch as imaging combined with drug delivery or photodynamic therapy.

9 r photocoagulation, CyberKnife radiation, or photodynamic therapy.

10 therapy, hyper- or hypothermic therapy, and photodynamic therapy.

11 s, which makes them potentially suitable for photodynamic therapy.

12 s in photothermal therapy, chemotherapy, and photodynamic therapy.

13 lation of photosensitizer drugs in tumors in photodynamic therapy.

14 for light-triggered biological reactions and photodynamic therapy.

15 n of disease and any previous treatment with photodynamic therapy.

16 ential as photosensitizers for metal-organic photodynamic therapy.

17 topical or injection interferon alfa-2b, and photodynamic therapy.

18 oxaliplatin chemotherapy, radiotherapy, and photodynamic therapy.

19 adverse effects, and cost, limit the use of photodynamic therapy.

20 itization, a limitation often encountered in photodynamic therapy.

21 rget proteins or to kill cell populations in photodynamic therapy.

22 itor, sensitizes xenotransplanted tumours to photodynamic therapy.

23 gulation, multipolar electrocoagulation, and photodynamic therapy.

24 plications in photobiology or O2-independent photodynamic therapy.

25 otactic radio surgery, and vascular-targeted photodynamic therapy.

26 modified silica nanoparticles for two-photon photodynamic therapy.

27 nding probes and photosensitizers for use in photodynamic therapy.

28 role of singlet oxygen and (1)O2 carriers in photodynamic therapy.

29 as effective and well-tolerated as daylight photodynamic therapy.

30 VEGF) interventions, dietary supplements, or photodynamic therapy.

31 econtouring, and antitumor and antimicrobial photodynamic therapy.

32 echanism for PIT as compared to conventional photodynamic therapies.

33 alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), photodynamic therapy (0% vs 1%), excisional biopsy and c

34 therapy and the other half treated with AWL photodynamic therapy 1 week apart and randomly allocated

35 randomly assigned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously

36 Photodynamic therapy, a combination of photosensitizer a

37 Vascular-targeted photodynamic therapy, a novel tissue-preserving treatmen

38 ing oxidant production by transition metals, photodynamic therapy, activated macrophages, and platele

39 This photodynamic therapy agent with a built-in apoptosis sen

40 hospholipid monolayer or with the lipophilic photodynamic therapy agent, tetra-t-butyl-silicon phthal

41 bial and antiviral agents, anticancer drugs, photodynamic therapy agents, radiotherapy agents and bio

42 occurs following topical aminolevulinic acid-photodynamic therapy (ALA-PDT), but its nature and media

43 or 0.5 mg), sham injections plus verteporfin photodynamic therapy (ANCHOR), or sham injections alone

44 y assigned 206 patients to vascular-targeted photodynamic therapy and 207 patients to active surveill

45 e findings may help to alleviate pain during photodynamic therapy and also allow for disease modifica

46 mes were after vs before the introduction of photodynamic therapy and anti-vascular endothelial growt

47 Combination therapy incorporating photodynamic therapy and antivascular endothelial growth

48 ffectiveness and adverse effects of daylight photodynamic therapy and artificial white light (AWL) LE

49 lly be a NIR photosensitizer and emitter for photodynamic therapy and bioimaging applications.

50 potential for applications in the fields of photodynamic therapy and cellular imaging.

51 e optogenetic control over neurons, targeted photodynamic therapy and deep tissue imaging.

52 Photodynamic therapy and radiofrequency ablation are rec

53 ies based on oxygen free radicals, including photodynamic therapy and radiotherapy, have emerged as p

54 ad half of their scalp treated with daylight photodynamic therapy and the other half treated with AWL

55 Of the new non-invasive treatments, only photodynamic therapy and topical imiquimod have become e

56 e studies that evaluated submacular surgery, photodynamic therapies, and anti-angiogenic therapies, a

57 diagnostics and analytics, photothermal and photodynamic therapies, and delivery of target molecules

58 emonstrates a highly promising new agent for photodynamic therapy, and attracts attention to photosta

59 peutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiothe

60 re interesting for model enzymes, catalysis, photodynamic therapy, and electron transfer.

61 Treatments such as stenting, photodynamic therapy, and novel pharmaceutical agents ar

62 al in coordination chemistry, anion sensing, photodynamic therapy, and optoelectronics.

63 ch terms solar keratosis, actinic keratosis, photodynamic therapy, and photochemotherapy.

64 Ablative treatments, including Nd:YAG laser, photodynamic therapy, and thermal contact treatments hav

65 ts of repeated applications of antimicrobial photodynamic therapy (aPDT) adjunctive to scaling and ro

66 im of this study is to compare antimicrobial photodynamic therapy (aPDT) as an adjunctive therapy to

67 Antimicrobial photodynamic therapy (aPDT) as an adjunctive treatment i

68 Antimicrobial photodynamic therapy (aPDT) is an emerging treatment for

69 a promising photosensitizer in antimicrobial photodynamic therapy (aPDT).

70 low-intensity laser (LIL); 2) antimicrobial photodynamic therapy (aPDT); or 3) toluidine blue O (TBO

71 mus) and the most promising absorptivity for photodynamic therapy application, was tested as efficien

72 contrast generation settings, as well as its photodynamic therapy application.

73 Near-IR absorption, desired for potential photodynamic therapy applications, was not pursuable for

74 Oncolytic viral therapy and photodynamic therapy are potential therapies for inopera

75 ession in cancer cells and susceptibility to photodynamic therapy based on their increased ability to

76 e most promising candidate in this study for photodynamic therapy because it has the longest waveleng

77 atoses (AKs) is as effective as conventional photodynamic therapy but has the advantage of being almo

78 Photodynamic therapy can be an effective alternative for

79 cations, including therapeutic (photothermal/photodynamic therapy, chemotherapy and synergistic thera

80 prolonging long-term survival, and although photodynamic therapy combined with stenting has been rep

81 Photodynamic therapy combining nanotechnology has shown

82 Here we demonstrate a photodynamic therapy construct that integrates both a cy

83 -VEGF therapy increased from 60.3% to 72.7%, photodynamic therapy decreased from 12.8% to 5.3%, and t

84 Photodynamic therapy delivers a value gain (improvement

85 Rose bengal- and riboflavin-mediated photodynamic therapy demonstrated complete growth inhibi

86 imaging and synergetic photothermal therapy/photodynamic therapy derived from the porphyrin-like moi

87 osensitizers into nanostructures can improve photodynamic therapy efficacy and the safety profile of

88 niques include endoscopic mucosal resection, photodynamic therapy, electrocoagulation, and laser ther

89 as photosynthesis, vision, photolithography, photodynamic therapy, etc., is yet to become a common to

90 re to sunlight and other patients undergoing photodynamic therapy experience similar pain, which can

91 e variety of potential applications, such as photodynamic therapy for accelerated drug screening, mag

92 diotherapy, brachytherapy, radiosurgery, and photodynamic therapy for recurrent high-grade glioma.

93 therapy and artificial white light (AWL) LED photodynamic therapy for the treatment of AKs on the for

94 cholangiopancreatography, and refinements in photodynamic therapy for the treatment of cholangiocarci

95 eporfin (VP), a light-activated drug used in photodynamic therapy for the treatment of choroidal neov

96 The use of endoscopic mucosal resection and photodynamic therapy for treatment of dysplastic Barrett

97 was 58 (28%) of 206 in the vascular-targeted photodynamic therapy group compared with 120 (58%) of 20

98 101 (49%) men in the vascular-targeted photodynamic therapy group had a negative prostate biops

99 tatitis (three [2%] in the vascular-targeted photodynamic therapy group vs one [<1%] in the active su

100 rious adverse event in the vascular-targeted photodynamic therapy group was retention of urine (15 pa

101 Photodynamic therapy guided by ERCP may provide improved

102 Photodynamic therapy has a 14%better chance of complete

103 Methyl aminolevulinate photodynamic therapy has been effective in 1 case but in

104 The non-invasive photodynamic therapy has been limited to treat superfici

105 for phototherapeutic interventions, such as photodynamic therapy, has transformed medicine and biolo

106 Daylight photodynamic therapy, however, requires dry and warm wea

107 The Microneedle Photodynamic Therapy II (MNPDT-II) study was a randomize

108 Among these, photodynamic therapy in addition to biliary stent placem

109 strated the enhanced role of cholangioscopy, photodynamic therapy in cholangiocarcinoma, and biliary

110 Photodynamic therapy in combination with antivascular en

111 lar endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemot

112 d treatment with the possibility of combined photodynamic therapy in refractory cases.

113 inical trials suggest excellent efficacy for photodynamic therapy in the treatment of subretinal neov

114 Photodynamic therapy, in which malignant tissue is kille

115 Newer modalities such as photodynamic therapy, intraluminal brachytherapy, and hi

116 interventions (argon laser photocoagulation, photodynamic therapy, intravitreal corticosteroids, and

117 TERPRETATION: Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for

118 Padeliporfin vascular-targeted photodynamic therapy is a safe, effective treatment for

119 Photodynamic therapy is the combination of non-toxic pho

120 iolet and visible light, and also to develop photodynamic therapy, it is important to resolve the mec

121 notherapy or combination IVB and verteporfin photodynamic therapy (IVB/PDT).

122 Photodynamic therapy looks extremely promising for adjun

123 Photodynamic therapy may be an effective therapeutic opt

124 ndoscopic therapies including mucosectomy or photodynamic therapy may be emerging options in patients

125 Photodynamic therapy, mediated by exogenously administer

126 ng for subsequent surgical excision (n = 3), photodynamic therapy (n = 1), or cryotherapy (n = 1) for

127 bles can act as ideal miniature reactors for photodynamic therapy of cancer cells.

128 frared light, which has great implication in photodynamic therapy of deep-tissue cancers.

129 guided sensitizer delivery for the potential photodynamic therapy of hypoxic structures requiring cyt

130 ensitizers for use as antimicrobial drugs in photodynamic therapy of localized infections.

131 vironments and (ii) "trackable" NO donors in photodynamic therapy of malignancies (such as skin cance

132 omedical applications is exemplified here as photodynamic therapy of malignancies.

133 croneedles could be a promising approach for photodynamic therapy of skin tumors.

134 zed and investigated as photosensitizers for photodynamic therapy of tumors.

135 locyanines are promising sensitizers for the photodynamic therapy of tumors.

136 bined with protoporphyrin IX (PpIX)-mediated photodynamic therapy on a variety of human pancreatic ca

137 gnosed as having exudative ARMD who received photodynamic therapy or anti-VEGF therapy compared with

138 Nonsurgical treatment by photodynamic therapy or mucosal resection may be a less

139 onthermal ablation with alcohol injection or photodynamic therapy, or displacement of tumor with endo

140 Case studies of photodynamic therapy, oral pentoxyphylline and hyperbari

141 ffect compared with reovirus monotherapy and photodynamic therapy (p=0.042) with 100% cell death obse

142 otic lesions followed by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.

143 ing pigment (methylene blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans

144 We have designed a novel photodynamic therapy (PDT) agent using protein binding a

145 es are needed to identify and optimize novel photodynamic therapy (PDT) agents with greater efficacy

146 ypyridyl complexes show great promise as new photodynamic therapy (PDT) agents.

147 rties were investigated for use as potential photodynamic therapy (PDT) agents.

148 e recently contributed to the progression of photodynamic therapy (PDT) and microbial photodynamic in

149 cy ablation (RFA), but other data pertain to photodynamic therapy (PDT) and other modalities.

150 , presumably through the combined effects of photodynamic therapy (PDT) and released chemotherapy dru

151 Cationic antimicrobial peptides (CAMPs) and photodynamic therapy (PDT) are attractive tools to comba

152 inical experiments addressing the effects of photodynamic therapy (PDT) as an adjunct to conventional

153 and imaging functions in one agent, choosing photodynamic therapy (PDT) as an appropriate cancer trea

154 This study investigates the effect of photodynamic therapy (PDT) as monotherapy during support

155 opportunities of NP imaging and therapy on a photodynamic therapy (PDT) based NP system that has been

156 Photodynamic therapy (PDT) can destroy local tumors and

157 we have found that addition of erlotinib to photodynamic therapy (PDT) can improve treatment respons

158 The efficacy of photodynamic therapy (PDT) depends upon the delivery of

159 A highly efficient drug vector for photodynamic therapy (PDT) drug delivery was developed b

160 Photodynamic therapy (PDT) efficacy is limited by the ve

161 neration and exhibits significantly enhanced photodynamic therapy (PDT) efficacy on two colon cancer

162 Moreover, it could be shown that photodynamic therapy (PDT) elevates antitumor immune res

163 Photodynamic therapy (PDT) elicits both apoptotic and ne

164 n angiograms taken before and 3 months after photodynamic therapy (PDT) for CNV (6 patients, group 1)

165 Photodynamic therapy (PDT) for high-grade dysplasia (HGD

166 vitro, including both chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer.

167 Photodynamic therapy (PDT) has been applied in cancer tr

168 Photodynamic therapy (PDT) has been shown to be effectiv

169 Photodynamic therapy (PDT) has been successfully used to

170 In recent years photodynamic therapy (PDT) has received widespread atten

171 n photoreceptor degeneration associated with photodynamic therapy (PDT) in a laser-induced model of c

172 mate visual system after a single session of photodynamic therapy (PDT) in an intact nonhuman primate

173 for their potential as photosensitizers for photodynamic therapy (PDT) in P-glycoprotein (P-gp) expr

174 herapy in ancient texts and the discovery of photodynamic therapy (PDT) in the early 1900s, the landm

175 We observed that photodynamic therapy (PDT) induces the expression and ph

176 Photodynamic therapy (PDT) involves the intravenous admi

177 Photodynamic therapy (PDT) is a clinically approved anti

178 Photodynamic therapy (PDT) is a Food and Drug Administra

179 Photodynamic therapy (PDT) is a light-based treatment mo

180 Photodynamic therapy (PDT) is a modality for the treatme

181 Photodynamic therapy (PDT) is a new strategy for treatin

182 Photodynamic therapy (PDT) is a promising approach to tr

183 Photodynamic therapy (PDT) is a promising treatment stra

184 Photodynamic therapy (PDT) is a rapidly developing appro

185 Photodynamic therapy (PDT) is a relatively new therapy t

186 Photodynamic therapy (PDT) is a technique developed to t

187 Photodynamic therapy (PDT) is an alternative treatment f

188 Photodynamic therapy (PDT) is an effective and cosmetica

189 Photodynamic therapy (PDT) is an effective anticancer pr

190 Photodynamic therapy (PDT) is an efficacious treatment f

191 Photodynamic therapy (PDT) is an important cancer treatm

192 Photodynamic therapy (PDT) is generally based on the gen

193 Photodynamic therapy (PDT) is now an approved therapeuti

194 Photodynamic therapy (PDT) is used extensively to treat

195 Photodynamic therapy (PDT) is widely used to treat diver

196 Photodynamic therapy (PDT) is widely used to treat non-m

197 With the knowledge that the dominant photodynamic therapy (PDT) mechanism of 1a (WST09) switc

198 ial of this conjugate as photosensitizer for photodynamic therapy (PDT) of cancers overexpressing the

199 cteriochlorins are attractive candidates for photodynamic therapy (PDT) of diverse medical indication

200 onthly ranibizumab (0.3 or 0.5 mg) with sham photodynamic therapy (PDT) or sham ocular injections wit

201 e purpose of this study was to determine how photodynamic therapy (PDT) promotes stabilization and re

202 Singlet oxygen sensitized photodynamic therapy (PDT) relies on the concentration o

203 Photodynamic therapy (PDT) stands to benefit from improv

204 Although photodynamic therapy (PDT) takes advantage of the spatia

205 very (fluence rate) plays a critical role in photodynamic therapy (PDT) through its control of tumor

206 treatment, it allowed delivery of selective photodynamic therapy (PDT) to the cancerous tissues, wit

207 Furthermore, immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors t

208 e entrapped agents that harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that

209 3 months, additional treatment with laser or photodynamic therapy (PDT) was considered if any fluores

210 A new approach to selective photodynamic therapy (PDT) was developed by designing ch

211 chanisms how the efficacy of photofrin based photodynamic therapy (PDT) was enhanced by miR-99a trans

212 racellular localization and cell response to photodynamic therapy (PDT) were analyzed in MCF10A norma

213 Photodynamic therapy (PDT) with 5-aminolevulinic acid (A

214 integration of fluorescence imaging (FL) and photodynamic therapy (PDT) with positron emission tomogr

215 Photodynamic therapy (PDT) with protoporphyrin IX (PpIX)

216 2 and Bcl-xL, are recognized phototargets of photodynamic therapy (PDT) with the mitochondrion-target

217 nalysis evaluated patients who had undergone photodynamic therapy (PDT) within the preceding year (N

218 val of combining surgery with intraoperative photodynamic therapy (PDT), a light-based cancer treatme

219 nstrate that benzoporphyrin derivative-based photodynamic therapy (PDT), a photochemical cytotoxic mo

220 Photodynamic therapy (PDT), a photochemistry-based cytot

221 Photodynamic therapy (PDT), also known as photoradiation

222 f cancer and dermatological diseases through photodynamic therapy (PDT), and advanced materials for e

223 nd emerging therapies, such as radiation and photodynamic therapy (PDT), can induce angiogenic molecu

224 In photodynamic therapy (PDT), cells are impregnated with a

225 additional limitations of porphyrin-mediated photodynamic therapy (PDT), including low depths of tiss

226 ent procedures, such as laser irradiation or photodynamic therapy (PDT), may provide some additional

227 anced technologies such as optical limiting, photodynamic therapy (PDT), organic field-effect transis

228 each clinical treatment tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by contro

229 In the case of photodynamic therapy (PDT), two-photon absorption combin

230 ptake of photosensitizers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma m

231 Photodynamic therapy (PDT), wherein light sensitive non-

232 PCI is founded upon the principle of photodynamic therapy (PDT), which uses light to activate

233 ing because (1)O2 plays an important role in photodynamic therapy (PDT).

234 or as the shell for potential application in photodynamic therapy (PDT).

235 erapy (PTT), and light to singlet oxygen for photodynamic therapy (PDT).

236 n investigated as photosensitizers (PSs) for photodynamic therapy (PDT).

237 at are illuminated, and this is the basis of photodynamic therapy (PDT).

238 a photosensitizer that acts as an agent for photodynamic therapy (PDT).

239 aptive immunity following treatments such as photodynamic therapy (PDT).

240 tment protocols, including dental lasers and photodynamic therapy (PDT).

241 esized and characterized as novel agents for photodynamic therapy (PDT).

242 al candidates for use as photosensitizers in photodynamic therapy (PDT).

243 ced choroidal neovascularization (CNV) after photodynamic therapy (PDT).

244 ors from collateral retinal damage caused by photodynamic therapy (PDT).

245 tioning and cellular membrane penetration in photodynamic therapy (PDT).

246 sing imaging agent and a photosensitizer for photodynamic therapy (PDT).

247 t respond well to either photocoagulation or photodynamic therapy (PDT).

248 ent protoporphyrin IX (PPIX) accumulation in photodynamic therapy (PDT).

249 et oxygen ((1) O2 ) is of great interest for photodynamic therapy (PDT).

250 ce lifetime microscopy (2PLM) and two-photon photodynamic therapy (PDT).

251 ture-activity relationships for their use in photodynamic therapy (PDT).

252 CP@pyrolipid) for effective chemotherapy and photodynamic therapy (PDT).

253 MRI contrasting agents, and sensitizers for photodynamic therapy (PDT); and more recently as models

254 (MARINA), or were randomized to verteporfin photodynamic therapy (PDT; n=143), 0.3-mg ranibizumab mo

255 Antibody-based photodynamic therapy-photoimmunotherapy (PIT)-is an idea

256 atform for the high-throughput assessment of photodynamic therapy photosensitizer (PDT) efficacy on E

257 addition, light activation has potential in photodynamic therapy, photothermal therapy, radiotherapy

258 , which is used as an antimicrobial agent in photodynamic therapy, potentiates tellurite toxicity.

259 Photodynamic therapy provided us with the first realisti

260 gated as cytotoxic agents and inhibitors, in photodynamic therapy, radiation therapy, drug/gene deliv

261 rapies were identified: electrochemotherapy, photodynamic therapy, radiotherapy, intralesional therap

262 Photodynamic therapy regimens, which use light-activated

263 Photodynamic therapy-related complications included intr

264 Two eyes received photodynamic therapy rescue during subsequent follow-up

265 Reovirus with PpIX-mediated photodynamic therapy resulted in a significantly increas

266 Photodynamic therapy's (PDT's) effects on the integrity

267 Photodynamic therapy simultaneously reduces plaque infla

268 Photodynamic therapy that uses photosensitizers which on

269 Prior to ocular photodynamic therapy the only available treatment was la

270 re either ineligible for or nonresponsive to photodynamic therapy, the standard treatment at the time

271 c function, which directs the development of photodynamic therapy to be safer and more selective.

272 s oncolytic viral therapy with PpIX-mediated photodynamic therapy to treat pancreatic cancer.

273 Photodynamic therapy using an AWL source was as effectiv

274 Photodynamic therapy using porfimer (P-PDT) improves pal

275 Daylight photodynamic therapy using topical methyl 5-aminolevulin

276 Photodynamic therapy using verteporfin at a dose of 6 mg

277 on with Photodynamic Therapy; Verteporfin in Photodynamic Therapy; VEGF Inhibition Study in Ocular Ne

278 ent of Age-Related Macular Degeneration with Photodynamic Therapy; Verteporfin in Photodynamic Therap

279 vitreal anti-VEGF injection; (3) verteporfin photodynamic therapy (vPDT); or (4) laser photocoagulati

280 xamine the hypothesis that vascular-targeted photodynamic therapy (VTP) with WST11 and clinically rel

281 The effect of adding reovirus after photodynamic therapy was also assessed.

282 Photodynamic therapy was associated with improved VA and

283 Next, the potential of SCPNs for photodynamic therapy was evaluated.

284 Their photosensitizing potential for photodynamic therapy was investigated in an in vitro mod

285 The potential of PPIX for photodynamic therapy was tested in vivo.

286 Vascular-targeted photodynamic therapy was well tolerated.

287 ects of reovirus combined with PpIX-mediated photodynamic therapy were analysed in methylthiazoltetra

288 Anti-VEGF agents and photodynamic therapy were the only interventions identif

289 omy, cryotherapy, laser photocoagulation, or photodynamic therapy, were excluded from the analysis.

290 in rare diseases, such as porphyrias, and in photodynamic therapy where short-term toxicity is intend

291 itization represents a promising approach in photodynamic therapy where the design of the active phot

292 Verteporfin (VP) was first used in Photodynamic therapy, where a non-thermal laser light (6

293 photothermal therapy and porphyrin-mediated photodynamic therapy which results in complete tumor eli

294 mour cells with low or no PTEN expression to photodynamic therapy, which is based on the ability of p

295 l of oral infections, including their use in photodynamic therapy, will be discussed in this review.

296 Photodynamic therapy with microneedle pretreatment at a

297 Photodynamic therapy with porfimer sodium combined with

298 Photodynamic therapy with the construct was successful i

299 f vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment o

300 ine) and their applications in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.